ConductScience.org, home

Paper41593124

Exploration of real-world outcomes in patients with previously treated HR+/HER2- and triple negative metastatic breast cancer.

Sadetsky N and 9 others. Sci Rep, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Exploration of real-world outcomes in patients with previously treated HR+/HER2- and triple negative metastatic breast cancer. Papers, record 41593124. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41593124

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Exploration of real-world outcomes in patients with previously treated HR+/HER2- and triple negative metastatic breast cancer.
PubMed
Journal
Sci Rep
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-07-01
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sadetsky NNatalia
2Prince PPatricia
3Latimer HHelen
4Advani PPooja
5Smith-Gaziani DDemetria
6Kaufman PAPeter A
7Natanzon YYanina
8Taylor AAliki
9Nguyen LLinda
10Freemantle NNick

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Triple Negative Breast NeoplasmsMajor topic
Erb-b2 Receptor Tyrosine KinasesMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Humans
Female
Treatment Outcome
Middle Aged
Fulvestrant
Paclitaxel
Receptors, Progesterone
Receptors, Estrogen
Pyridines
Aged
Neoplasm Metastasis
Progression-Free Survival
Adult
Piperazines

Source PubMed

Download CSV of topics

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131335166An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer.JCO Clin Cancer Inform2019https://conductscience.org/library/papers/31335166PubMed
230959874Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.Cells2019https://conductscience.org/library/papers/30959874PubMed
330345905Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.N Engl J Med2018https://conductscience.org/library/papers/30345905PubMed
436408668The Aetion Coalition to Advance Real-World Evidence through Randomized Controlled Trial Emulation Initiative: Oncology.Clin Pharmacol Ther2023https://conductscience.org/library/papers/36408668PubMed
517947786Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.BMJ2007https://conductscience.org/library/papers/17947786PubMed
639966355Breast cancer: pathogenesis and treatments.Signal Transduct Target Ther2025https://conductscience.org/library/papers/39966355PubMed
739146509Evaluation of Real-World Tumor Response Derived From Electronic Health Record Data Sources: A Feasibility Analysis in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Chemotherapy.JCO Clin Cancer Inform2024https://conductscience.org/library/papers/39146509PubMed
832546660Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows.Mol Cancer Ther2020https://conductscience.org/library/papers/32546660PubMed
937633306
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
Lancet2023https://conductscience.org/library/papers/37633306PubMed
1028743247A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).BMC Cancer2017https://conductscience.org/library/papers/28743247PubMed
1131394922Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer.J Comp Eff Res2019https://conductscience.org/library/papers/31394922PubMed
1235665782Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.N Engl J Med2022https://conductscience.org/library/papers/35665782PubMed
1335643624Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis.Clin Breast Cancer2022https://conductscience.org/library/papers/35643624PubMed
1423915742The management of early-stage and metastatic triple-negative breast cancer: a review.Hematol Oncol Clin North Am2013https://conductscience.org/library/papers/23915742PubMed
1527583878Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database.Medicine (Baltimore)2016https://conductscience.org/library/papers/27583878PubMed
1632315295Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer.PLoS One2020https://conductscience.org/library/papers/32315295PubMed
1726690726Transparency and Reproducibility of Observational Cohort Studies Using Large Healthcare Databases.Clin Pharmacol Ther2016https://conductscience.org/library/papers/26690726PubMed
1834664259The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies.Clin Pharmacol Ther2022https://conductscience.org/library/papers/34664259PubMed
1940669020Real-World Germline BRCA Testing, Poly(ADP-ribose) Polymerase Inhibitor Utilization, and Survival Outcomes in Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.JCO Precis Oncol2025https://conductscience.org/library/papers/40669020PubMed
2019097774New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer2009https://conductscience.org/library/papers/19097774PubMed

See all 35 referencesDownload CSV of references

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41593124

GET https://conductscience.org/api/papers/v1/41593124/references?page=2